• First Tracks Biotherapeutics posted a wider net loss of USD 50.5 million for three months ended March 31, 2026, while research and development expense fell 18.1% to USD 34 million.
• General and administrative expense more than doubled to USD 18.9 million, while interest income dropped 43.9% to USD 2.3 million.
• Cash and cash equivalents totaled USD 286.5 million at March 31, down from USD 311.6 million at Dec. 31, 2025, with operating cash outflow narrowing to USD 32.6 million from USD 45 million a year earlier.
• Spin-off from AnaptysBio completed April 20, 2026, followed immediately by a private placement that raised about USD 80 million in gross proceeds at USD 13.81 per share.
• Pipeline update included ongoing Phase 1b cohorts for ANB033 in celiac disease and eosinophilic esophagitis, plus an End-of-Phase 2 FDA meeting for rosnilimab in rheumatoid arthritis completed in first quarter 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. First Tracks Biotherapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-224190), on May 14, 2026, and is solely responsible for the information contained therein.